INTRODUCTION AND OBJECTIVES: Dyslipidemia (DL) is a critical comorbidity that occurs after renal transplantation and can lead to cardiovascular diseases. The relationship between the development of DL and glucocorticoid receptor (NR3C1) polymorphism was previously reported by the authors. However, a confirmation study of the implication of DL in polymorphism and the effect of DL on allograft prognosis has not been conducted yet. In this study, we validated the clinical implications of the NR3C1 Bcl I G allele and assessed risk factors for developing DL and graft survival.
INTRODUCTION AND OBJECTIVES: Dyslipidemia (DL) is a critical comorbidity that occurs after renal transplantation and can lead to cardiovascular diseases. The relationship between the development of DL and glucocorticoid receptor (NR3C1) polymorphism was previously reported by the authors. However, a confirmation study of the implication of DL in polymorphism and the effect of DL on allograft prognosis has not been conducted yet. In this study, we validated the clinical implications of the NR3C1 Bcl I G allele and assessed risk factors for developing DL and graft survival.
METHODS: Two hundred forty-seven consequent renal allograft recipients (153 men and 94 women) who underwent transplantation under tacrolimus (TAC)-based immunosuppression between February 2002 and August 2015 were evaluated. Susceptibility to DL was validated in 76 recipients who underwent transplantation between September 2011 and August 2015. Risk factors for developing DL and allograft prognosis were assessed in all the 247 patients.
RESULTS: In the validation study, the incidence of DL was significantly higher in the patients with the NR3C1 Bcl I G allele than in those with the CC genotype (p ¼ 0.009). After validation, 92 recipients (37.2%) were diagnosed as having DL after transplantation. No significant differences in mean body mass index, acute rejection rate, ABO incompatibility, and the incidence of diabetes mellitus or hyperuricemia were observed. The occurrence of DL was associated with female sex and older age (p ¼ 0.002 and 0.026, respectively). No significant differences were observed in the immunosuppressant pharmacokinetic parameters. The incidence of DL was significantly higher in the patients with the NR3C1 Bcl I G allele than in those with the CC genotype (p ¼ 0.002). The multivariate analysis revealed that the NR3C1 Bcl I G allele, female sex, and age of >47 years were significant risk factors for developing DL (odds ratios, 2.16, 2.43, and 1.78, respectively; 95% confidence intervals, 1.24-3.76, 1.39-4.24, and 1.07-3.26, respectively; Table 1 ). No significant difference in graft survival was found between the two groups.
CONCLUSIONS: The incidence of DL in our cohort was 37.2%. The NR3C1 Bcl I G allele may allow prediction of the occurrence of DL. These findings may aid in predicting patients 0 risk of developing DL.
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MP74-09 FOCAL ABLATIVE THERAPY FOR SOLID RENAL MASSES IN TRANSPLANT ALLOGRAFT KIDNEYS
John Griffith*, Aaron Fischman, Nikhil Waingankar, Michael Palese, John Sfakianos, Ketan Badani, Reza Mehrazin, New York, NY INTRODUCTION AND OBJECTIVES: Renal transplantation is the gold-standard treatment for end-stage renal disease (ESRD). It is known that transplant patients are at an increased risk of developing denovo malignancy, with initial evidence showing an increased risk of solid renal masses (SRMs) in the transplant allograft kidney compared to the overall population. Definitive management of SRMs in transplanted allograft kidneys is a difficult clinical scenario due to complex surgical anatomy, postoperative adhesions, and need for renal preservation. The aim of this study was to review a single institutional experience with focal ablative therapies for SRMS in transplant allograft kidneys.
METHODS: After institutional review board approval, patients with a history of SRM in transplanted allograft kidneys who underwent focal ablative therapy were identified. Complete chart review was performed with relevant data extracted for cumulative analysis.
RESULTS: Five patients treated with focal ablative therapy of a SRM in a transplanted allograft kidney were identified from 2010-2015 at our institution. Two underwent percutaneous microwave ablation, one percutaneous irreversible electroporation ablation, one laparoscopic cryoablation, and one open cryoablation. Median mass size was 2.8cm (range 1.6-3.4cm). SRMs were diagnosed at a median of 96 months (range 1-96 months) after transplantation, with three patients having undergone living donor transplantation and two receiving cadaveric grafts. Tumor histology included 3 clear cell renal cell carcinoma (RCC), 1 papillary RCC, and 1 had no available pathology. One mass had a Furhman grade of 3 and the other three available histologies were classified as Fuhrman grade 1-2. Two patients experienced postoperative complications, with one patient developing a hematoma requiring drainage (Clavien IIIa), and another patient developing a hematoma managed conservatively (Clavien I). Four patients had no evidence of disease at a median follow up of 30 months (range 9-60 months). One patient developed metastatic disease 48 months following ablation. All patients had stable GFR after ablation, with none requiring a return to dialysis.
CONCLUSIONS: Our single institution case series presents the largest reported series of focal ablative therapies for SRMs in transplant allograft kidneys. Our experience shows, with intermediate term follow up that focal ablative therapies are a feasible renal-sparing intervention for management of SRMs in transplant allograft kidneys.
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